Panel a. Patient examples. Patient 1 had no fibrosis on CMR-1, on follow-up imaging midwall fibrosis is seen in the basal septum (yellow arrows) which is a typical finding on non-ischemic DCM. Patient 2 had midwall fibrosis on CMR-1, which has progressed on CMR-2.
Panel b. The difference in overall survival in patients with progressive fibrosis and stable fibrosis was significant (p=0.03, by the log rank test). There was also a significant difference in major adverse cardiovascular event (MACE) (p<0.01, by the log rank test).